Carcinoma, Neuroendocrine
"Carcinoma, Neuroendocrine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A group of carcinomas which share a characteristic morphology, often being composed of clusters and trabecular sheets of round "blue cells", granular chromatin, and an attenuated rim of poorly demarcated cytoplasm. Neuroendocrine tumors include carcinoids, small ("oat") cell carcinomas, medullary carcinoma of the thyroid, Merkel cell tumor, cutaneous neuroendocrine carcinoma, pancreatic islet cell tumors, and pheochromocytoma. Neurosecretory granules are found within the tumor cells. (Segen, Dictionary of Modern Medicine, 1992)
| Descriptor ID |
D018278
|
| MeSH Number(s) |
C04.557.465.625.650.240 C04.557.470.200.025.370 C04.557.580.625.650.240
|
| Concept/Terms |
Carcinoma, Neuroendocrine- Carcinoma, Neuroendocrine
- Carcinomas, Neuroendocrine
- Neuroendocrine Carcinoma
- Neuroendocrine Carcinomas
|
Below are MeSH descriptors whose meaning is more general than "Carcinoma, Neuroendocrine".
Below are MeSH descriptors whose meaning is more specific than "Carcinoma, Neuroendocrine".
This graph shows the total number of publications written about "Carcinoma, Neuroendocrine" by people in this website by year, and whether "Carcinoma, Neuroendocrine" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2003 | 1 | 0 | 1 |
| 2005 | 1 | 0 | 1 |
| 2009 | 0 | 1 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 1 | 2 |
| 2012 | 2 | 1 | 3 |
| 2013 | 1 | 3 | 4 |
| 2016 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 0 | 2 |
| 2021 | 1 | 0 | 1 |
| 2022 | 1 | 1 | 2 |
| 2023 | 1 | 0 | 1 |
| 2024 | 2 | 0 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Carcinoma, Neuroendocrine" by people in Profiles.
-
Medullary Thyroid Cancer: Single Institute Experience Over 3 Decades and Risk Factors for Recurrence. J Clin Endocrinol Metab. 2024 Oct 15; 109(11):2729-2734.
-
Clinicopathologic and Molecular Characterization of Inflammatory Bowel Disease-Associated Neuroendocrine Carcinomas and Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Mod Pathol. 2024 Oct; 37(10):100566.
-
Medullary Thyroid Carcinoma and Population Screening-The Promise and Pitfalls of Genetic Testing. JAMA Otolaryngol Head Neck Surg. 2023 03 01; 149(3):202-203.
-
Selpercatinib-Induced Hypothyroidism Through Off-Target Inhibition of Type 2 Iodothyronine Deiodinase. JCO Precis Oncol. 2022 06; 6:e2100496.
-
First Differentiate and Then Operate (Or Not) : Editorial on "Surgical Treatment of Patients with Poorly Differentiated Pancreatic Neuroendocrine Carcinoma: An NCDB Analysis". Ann Surg Oncol. 2022 06; 29(6):3371-3372.
-
Addressing Sex Disparities in Lung Cancer Screening Eligibility: USPSTF vs PLCOm2012 Criteria. Chest. 2022 01; 161(1):248-256.
-
Clinicopathologic Features and Survival Outcomes for Primary Renal Neuroendocrine Neoplasms. Clin Genitourin Cancer. 2021 04; 19(2):155-161.
-
MUC1-C regulates lineage plasticity driving progression to neuroendocrine prostate cancer. Nat Commun. 2020 01 17; 11(1):338.
-
Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors. Cancer. 2019 04 15; 125(8):1247-1257.
-
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers. Clin Cancer Res. 2019 01 01; 25(1):43-51.